Table 4.
References for urinary 8-OHdG concentrations measured and computed GM (ng/mg creatinine) with immunological techniques in healthy (mean BMI ≤ 25 and no known disease), adult (18+ years) participants.
| Reference | Study Group | Sample | Country | Sample Size | Mean Age | Female | Male | Smoking Status | Mean BMI | AM | GM | IQR | Range | Median | CI | Units (8-OHdG/Creatinine) | Computed GM (ng/mg Creatinine) | GSD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [50] | Healthy control group | 24 h urine | Thailand | 30 | 41.43 | 19 | 11 | NA | 22.56 | 4.32 ± 4.93 * | μg/g | 3 | 2 | |||||
| [51] | Healthy control group | 24 h urine | Thailand | 30 | 41.43 | 19 | 11 | NA | 22.56 | 5.27 ± 2.77 * | μg/g | 5 | 2 | |||||
| [52] | Control group | spot urine | China | 35 | 60 | 15 | 20 | 0% | 22.9 | 11.9 ± 4.9 * | ng/mg | 11 | 1 | |||||
| [53] | Control group | spot urine | Korea | 416 | 64.4 | 92 | 324 | 28.1% | 23.7 | 5.06 | 4.55–5.62 | μg/g | 5 | 2 | ||||
| [54] | Control group | spot urine | Korea | 140 | 68.8 | 32 | 108 | 65.5% | 22.46 | 4.88 | 4.43–5.38 | μg/g | 5 | 1 | ||||
| [55] | Healthy young group | 24 h urine | Canada | 12 | 22.8 | 0 | 12 | 0% | 25 | 5333 ± 1191 * | ng/g | 5 | 1 | |||||
| [56] | Apple group final value | spot urine | China | 13 | 62.8 | 3 | 10 | 0% | 24.2 | 824.41 ± 343.66 * | ng/mmol | 7 | 1 | |||||
| [56] | Pomegranate group final value | spot urine | China | 13 | 64.1 | 3 | 10 | 0% | 23 | 651.57 ± 332.44 * | ng/mmol | 5 | 2 | |||||
| [57] | placebo group baseline value | spot urine | China | 150 | 51.58 | 92 | 58 | 41.3% | 23.8 | 60.89 ± 1.62* | 58.19 | ng/mg | 61 | 2 | ||||
| [57] | Baseline line value Low FA group | spot urine | China | 145 | 48.9 | 87 | 58 | 33.8% | 24.5 | 55.48 ± 1.74 * | 53.51 | ng/mg | 55 | 2 | ||||
| [57] | Baseline value high FA group | spot urine | China | 143 | 48.66 | 94 | 49 | 30.1% | 24.6 | 55.81 ± 1.72 * | 54.73 | ng/mg | 56 | 2 | ||||
| [58] | Control group | 24 h urine | Japan | 15 | 40 | 6 | 9 | 0% | 23.2 | 9.7 ± 4.6 * | ng/mg | 9 | 2 | |||||
| [59] | Control group I | spot urine | China | 20 | 25.55 | 17 | 3 | 0% | 19.74 | 10.68 ± 1.07 ** | ng/mg | 10 | 2 | |||||
| [59] | Control group II | spot urine | China | 20 | 24.5 | 15 | 5 | 0% | 20.09 | 11.96 ± 0.73 ** | ng/mg | 12 | 1 | |||||
| [60] | Male group | spot urine | Japan | 195 | 41.7 | 0 | 195 | 49.7% | 23.6 | 9.35 ± 3.66 * | ng/mg | 9 | 1 | |||||
| [60] | Female group | spot urine | Japan | 194 | 41.7 | 194 | 0 | 29.9% | 22.1 | 10.97 ± 5 * | ng/mg | 10 | 2 | |||||
| [61] | Non MS group | spot urine | Japan | 638 | 40.8 | 385 | 253 | 27.3% | 22.3 | 9.28 ± 4.15 * | ng/mg | 8 | 2 | |||||
| [62] | Male control | spot urine | Pakistan | 34 | 39.7 | 0 | 34 | 0% | 19.85 | 24.5 ± 6.6 * | 11.08–33.85 | 25.72 | ng/mg | 26 | 1 | |||
| [62] | Female control | spot urine | Pakistan | 32 | 39.52 | 32 | 0 | 0% | 20.83 | 24.5 ± 6.33 * | 11.1–33.85 | 24.47 | ng/mg | 24 | 1 | |||
| [63] | Control group | spot urine | Pakistan | 34 | 39.7 | 0 | 34 | 0% | 20.9 | 24 ± 4 * | 9–30 | 25 | ng/mg | 25 | 1 | |||
| [64] | Control group | spot urine | Pakistan | 34 | 37 | 0 | 34 | 0% | 20.8 | 25.8 ± 7 * | 9.1–33.9 | 27.9 | ng/mg | 28 | 1 | |||
| [65] | Pregnant women | spot urine | Korea | 261 | 29.6 | 261 | 0 | 0% | 21 | 20.8 ± 14.2 * | µg/g | 17 | 2 | |||||
| [66] | Control group baseline | spot urine | UK | 32 | 31.7 | 15 | 17 | 0% | 22.4 | 21.6 ± 12.6 * | ng/mg | 19 | 2 | |||||
| [66] | Test group baseline | spot urine | UK | 32 | 31.7 | 15 | 17 | 0% | 22.4 | 24 ± 13.3 * | ng/mg | 21 | 2 | |||||
| [67] | Control group | spot urine | Turkey | 20 | 40.7 | 10 | 10 | NA | 22.52 | 7.84 ± 7.04 * | ng/mg | 6 | 2 | |||||
| [68] | Control group | spot urine | Japan | 108 | 23 | 0 | 108 | NA | 22.5 | 10.4 ± 3.2 * | ng/mg | 10 | 1 | |||||
| [69] | Non exposed group | spot urine | Iran | 43 | 35.58 | 0 | 43 | 21% | 19–24 | 54.16 ± 26.98 * | ng/mg | 48 | 2 | |||||
| [70] | Control group | spot urine | Japan | 52 | 62.4 | 27 | 25 | 0% | 24 | 8.8 ± 0.5 ** | ng/mg | 8 | 1 | |||||
| [71] | Male group | spot urine | Japan | 276 | 42.1 | 0 | 276 | NA | 23.8 | 8.8 ± 0.2 ** | ng/mg | 8 | 1 | |||||
| [71] | Female group | spot urine | Japan | 445 | 42.7 | 445 | 0 | NA | 21.9 | 9.8 ± 0.2 ** | ng/mg | 9 | 2 | |||||
| [72] | Male healthy population | spot urine | Japan | 142 | 43.6 | 0 | 142 | 31% | 22.4 | 11.5 ± 5.2 * | ng/mg | 10 | 2 | |||||
| [72] | Female healthy population | spot urine | Japan | 136 | 43.4 | 136 | 0 | 52.2% | 23.8 | 9.4 ± 3.4 * | ng/mg | 9 | 1 | |||||
| [73] | Control group | spot urine | USA | 43 | 32.6 | 43 | 0 | 0% | 23.2 | 6.31 ± 2.49 * | ng/mg | 6 | 1 | |||||
| [74] | Male group | spot urine | Japan | 323 | 42 | 0 | 323 | 42.7% | 23.7 | 8.85 ± 3.29 | ng/mg | 8 | 1 | |||||
| [74] | Female group | spot urine | Japan | 443 | 42.7 | 443 | 0 | 13.5% | 21.9 | 9.89 ± 4.54 * | ng/mg | 9 | 2 | |||||
| [75] | Green tea catechin-no exercise group baseline value | spot urine | Japan | 8 | 22.4 | 0 | 8 | 0% | >18 <25 | 15.9 ± 3.6 * | ng/mg | 16 | 1 | |||||
| [75] | Green tea catechin-exercise group baseline value | spot urine | Japan | 8 | 21.1 | 0 | 8 | 0% | >18 <25 | 22.9 ± 7.9 * | ng/mg | 22 | 1 | |||||
| [75] | Placebo group | spot urine | Japan | 8 | 21.1 | 0 | 8 | 0% | >18 <25 | 18 ± 6.2 * | ng/mg | 17 | 1 | |||||
| [76] | Men group | spot urine | Japan | 272 | 43.5 | 0 | 272 | 60.7% | 23.7 | 8.86 ± 3.36 * | 2.13–21.87 | μg/g | 8 | 1 | ||||
| [76] | Women group | spot urine | Japan | 295 | 40.3 | 295 | 0 | 15.6% | 21.7 | 9.25 ± 4.03 * | 0.05–25.56 | μg/g | 8 | 2 | ||||
| [77] | Baseline value 50km group | spot urine | Italy | 6 | 41.83 | NA | NA | 0% | 21.08 | 4.38 ± 1.16 * | ng/mg | 4 | 1 | |||||
| [78] | Summer Non heating season | spot urine | China | 34 | 47.9 | 34 | 0 | 0% | 23.2 | 12.7 ± 4.7 * | 2.60, 25.8 | 13.6 | ng/mg | 9 | 2 | |||
| [79] | Healthy volunteers Young group | spot urine | Turkey | 30 | 41.6 | 22 | 8 | 0% | 22.1 | 3.24 ± 1.54 * | ng/mg | 3 | 2 | |||||
| [79] | Healthy volunteers Elderly group | spot urine | Turkey | 30 | 69.1 | 20 | 10 | 0% | 23.6 | 5.74 ± 2.68 * | ng/mg | 5 | 2 | |||||
| [80] | Baseline value | spot urine | China | 25 | 20.9 | 12 | 13 | 0% | 20.67 | 3765.63 ± 958.14 * | ng/mmol | 32 | 1 | |||||
| [15] | Women group | spot urine | Italy | 33 | 30 | 33 | 0 | 29% | 20.7 | 3.68–7.20 | 5.21 | ng/mg | 4 | 2 | ||||
| [81] | Non exposed group | spot urine | China | 143 | 27.89 | 100 | 43 | 8% | 21.03 | 17.36 ± 13.5 * | ng/mg | 14 | 2 |
* SD; ** SEM.